Clinical trials generally identify the most dangerous side effects of drugs, but they can fail to find what symptoms patients are most concerned about, says Lyle H
Rybelsus and Others Rybelsus is the first oral GLP-1 drug, offering an option for those who dont want injections
Important safety considerations during the initial treatment period include: Monitoring for severe gastrointestinal symptoms: Persistent vomiting, severe abdominal pain, or signs of pancreatitis (severe upper abdominal pain radiating to the back) require immediate medical evaluation
The Cochrane Database of Systematic Reviews , 3, CD005105
Fair-balance framing, not a buying recommendation
Triple-hormone-receptor agonist retatrutide for obesity, a phase 2 trial